rc48-adc
Neoplasms, Lung
Novartis Pharmaceuticalsantibody_drug_conjugatePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Neoplasms, Lung cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ris-Rez GlaxoSmithKline | Phase 3 | B |
Hycamtin GlaxoSmithKline | Phase 3 | B |
Aflibercept Sanofi | Phase 2 | B |
Ziv-Aflibercept Sanofi | Phase 2 | B |
esg401 Shanghai Escugen Biotechnology Co., Ltd | Phase 1/2 | CCC |
View all 10 →
Same molecule, other indications
rc48-adc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →